BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Xue S, Hu M, Li P, Ma J, Xie L, Teng F, Zhu Y, Fan B, Mu D, Yu J. Relationship between expression of PD-L1 and tumor angiogenesis, proliferation, and invasion in glioma. Oncotarget 2017;8:49702-12. [PMID: 28591697 DOI: 10.18632/oncotarget.17922] [Cited by in Crossref: 42] [Cited by in F6Publishing: 50] [Article Influence: 10.5] [Reference Citation Analysis]
Number Citing Articles
1 Tan J, Liu T, Fan W, Wei J, Zhu B, Liu Y, Liu L, Zhang X, Chen S, Lin H, Zhang Y, Li J. Anti-PD-L1 antibody enhances curative effect of cryoablation via antibody-dependent cell-mediated cytotoxicity mediating PD-L1highCD11b+ cells elimination in hepatocellular carcinoma. Acta Pharmaceutica Sinica B 2022. [DOI: 10.1016/j.apsb.2022.08.006] [Reference Citation Analysis]
2 Senhaji N, Squalli Houssaini A, Lamrabet S, Louati S, Bennis S. Molecular and Circulating Biomarkers in Patients with Glioblastoma. Int J Mol Sci 2022;23:7474. [PMID: 35806478 DOI: 10.3390/ijms23137474] [Reference Citation Analysis]
3 Pająk B. Looking for the Holy Grail—Drug Candidates for Glioblastoma Multiforme Chemotherapy. Biomedicines 2022;10:1001. [DOI: 10.3390/biomedicines10051001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Jain S, Chalif EJ, Aghi MK. Interactions Between Anti-Angiogenic Therapy and Immunotherapy in Glioblastoma. Front Oncol 2021;11:812916. [PMID: 35096619 DOI: 10.3389/fonc.2021.812916] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
5 Noronha C, Ribeiro AS, Taipa R, Leitão D, Schmitt F, Reis J, Faria C, Paredes J. PD-L1 tumor expression is associated with poor prognosis and systemic immunosuppression in glioblastoma. J Neurooncol. [DOI: 10.1007/s11060-021-03907-3] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Jin Y, Zuo HX, Li MY, Zhang ZH, Xing Y, Wang JY, Ma J, Li G, Piao H, Gu P, Jin X. Anti-Tumor Effects of Carrimycin and Monomeric Isovalerylspiramycin I on Hepatocellular Carcinoma in Vitro and in Vivo. Front Pharmacol 2021;12:774231. [PMID: 34899336 DOI: 10.3389/fphar.2021.774231] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
7 Nagaraju GP, Malla RR, Basha R, Motofei IG. Contemporary clinical trials in pancreatic cancer immunotherapy targeting PD-1 and PD-L1. Semin Cancer Biol 2021:S1044-579X(21)00270-4. [PMID: 34774995 DOI: 10.1016/j.semcancer.2021.11.003] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
8 Wang JY, Jiang MW, Li MY, Zhang ZH, Xing Y, Ri M, Jin CH, Xu GH, Piao LX, Jin HL, Ma J, Zuo HX, Jin X. Formononetin represses cervical tumorigenesis by interfering with the activation of PD-L1 through MYC and STAT3 downregulation. J Nutr Biochem 2021;:108899. [PMID: 34748924 DOI: 10.1016/j.jnutbio.2021.108899] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
9 Samman DME, Mahdy MME, Cousha HS, Kamar ZAER, Mohamed KAK, Gabal HHA. Immunohistochemical expression of programmed death-ligand 1 and CD8 in glioblastomas. J Pathol Transl Med 2021;55:388-97. [PMID: 34638219 DOI: 10.4132/jptm.2021.08.04] [Reference Citation Analysis]
10 Vimalathas G, Kristensen BW. Expression, prognostic significance and therapeutic implications of PD-L1 in gliomas. Neuropathol Appl Neurobiol 2021. [PMID: 34533233 DOI: 10.1111/nan.12767] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
11 Tufano M, D'Arrigo P, D'Agostino M, Giordano C, Marrone L, Cesaro E, Romano MF, Romano S. PD-L1 Expression Fluctuates Concurrently with Cyclin D in Glioblastoma Cells. Cells 2021;10:2366. [PMID: 34572014 DOI: 10.3390/cells10092366] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
12 Liu YS, Huang BR, Lin CJ, Shen CK, Lai SW, Chen CW, Lin HJ, Lin CH, Hsieh YC, Lu DY. Paliperidone Inhibits Glioblastoma Growth in Mouse Brain Tumor Model and Reduces PD-L1 Expression. Cancers (Basel) 2021;13:4357. [PMID: 34503167 DOI: 10.3390/cancers13174357] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
13 Fujii T, Hirakata T, Kurozumi S, Tokuda S, Nakazawa Y, Obayashi S, Yajima R, Oyama T, Shirabe K. VEGF-A Is Associated With the Degree of TILs and PD-L1 Expression in Primary Breast Cancer. In Vivo 2020;34:2641-6. [PMID: 32871794 DOI: 10.21873/invivo.12082] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
14 Bastaki S, Aravindhan S, Ahmadpour Saheb N, Afsari Kashani M, Evgenievich Dorofeev A, Karoon Kiani F, Jahandideh H, Beigi Dargani F, Aksoun M, Nikkhoo A, Masjedi A, Mahmoodpoor A, Ahmadi M, Dolati S, Namvar Aghdash S, Jadidi-Niaragh F. Codelivery of STAT3 and PD-L1 siRNA by hyaluronate-TAT trimethyl/thiolated chitosan nanoparticles suppresses cancer progression in tumor-bearing mice. Life Sci 2021;266:118847. [PMID: 33309720 DOI: 10.1016/j.lfs.2020.118847] [Cited by in Crossref: 7] [Cited by in F6Publishing: 16] [Article Influence: 3.5] [Reference Citation Analysis]
15 Lee DY, Im E, Yoon D, Lee YS, Kim GS, Kim D, Kim SH. Pivotal role of PD-1/PD-L1 immune checkpoints in immune escape and cancer progression: Their interplay with platelets and FOXP3+Tregs related molecules, clinical implications and combinational potential with phytochemicals. Semin Cancer Biol 2020:S1044-579X(20)30258-3. [PMID: 33301862 DOI: 10.1016/j.semcancer.2020.12.001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
16 Zhu Z, Zhang H, Chen B, Liu X, Zhang S, Zong Z, Gao M. PD-L1-Mediated Immunosuppression in Glioblastoma Is Associated With the Infiltration and M2-Polarization of Tumor-Associated Macrophages. Front Immunol 2020;11:588552. [PMID: 33329573 DOI: 10.3389/fimmu.2020.588552] [Cited by in Crossref: 7] [Cited by in F6Publishing: 27] [Article Influence: 3.5] [Reference Citation Analysis]
17 Zhang YF, Zhang ZH, Li MY, Wang JY, Xing Y, Ri M, Jin CH, Xu GH, Piao LX, Zuo HX, Jin HL, Ma J, Jin X. Britannin stabilizes T cell activity and inhibits proliferation and angiogenesis by targeting PD-L1 via abrogation of the crosstalk between Myc and HIF-1α in cancer. Phytomedicine 2021;81:153425. [PMID: 33310309 DOI: 10.1016/j.phymed.2020.153425] [Cited by in Crossref: 3] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
18 Seyedmirzaei H, Shobeiri P, Turgut M, Hanaei S, Rezaei N. VEGF levels in patients with glioma: a systematic review and meta-analysis. Rev Neurosci 2021;32:191-202. [PMID: 33125340 DOI: 10.1515/revneuro-2020-0062] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
19 Ding XC, Wang LL, Zhu YF, Li YD, Nie SL, Yang J, Liang H, Weichselbaum RR, Yu JM, Hu M. The Change of Soluble Programmed Cell Death-Ligand 1 in Glioma Patients Receiving Radiotherapy and Its Impact on Clinical Outcomes. Front Immunol 2020;11:580335. [PMID: 33224142 DOI: 10.3389/fimmu.2020.580335] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
20 Bolly HMB, Faried A, Hermanto Y, Lubis BP, Tjahjono FP, Hernowo BS, Arifin MZ. Analysis of Mutant Isocitrate Dehydrogenase 1 Immunoexpression, Ki-67 and Programmed Death Ligand 1 in Diffuse Astrocytic Tumours : Study of Single Center in Bandung, Indonesia. J Korean Neurosurg Soc 2021;64:100-9. [PMID: 33105535 DOI: 10.3340/jkns.2020.0071] [Reference Citation Analysis]
21 Zhang L, Li M, Zhou Q, Dang M, Tang Y, Wang S, Fu J, Teng Z, Lu G. Computed tomography and photoacoustic imaging guided photodynamic therapy against breast cancer based on mesoporous platinum with insitu oxygen generation ability. Acta Pharm Sin B 2020;10:1719-29. [PMID: 33088691 DOI: 10.1016/j.apsb.2020.05.003] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
22 Chen QH, Li B, Liu DG, Zhang B, Yang X, Tu YL. LncRNA KCNQ1OT1 sponges miR-15a to promote immune evasion and malignant progression of prostate cancer via up-regulating PD-L1. Cancer Cell Int 2020;20:394. [PMID: 32821247 DOI: 10.1186/s12935-020-01481-8] [Cited by in Crossref: 10] [Cited by in F6Publishing: 29] [Article Influence: 5.0] [Reference Citation Analysis]
23 Song N, Li P, Song P, Li Y, Zhou S, Su Q, Li X, Yu Y, Li P, Feng M, Zhang M, Lin W. MicroRNA-138-5p Suppresses Non-small Cell Lung Cancer Cells by Targeting PD-L1/PD-1 to Regulate Tumor Microenvironment. Front Cell Dev Biol 2020;8:540. [PMID: 32754587 DOI: 10.3389/fcell.2020.00540] [Cited by in Crossref: 9] [Cited by in F6Publishing: 15] [Article Influence: 4.5] [Reference Citation Analysis]
24 Zuo HX, Jin Y, Wang Z, Li MY, Zhang ZH, Wang JY, Xing Y, Ri MH, Jin CH, Xu GH, Piao LX, Ma J, Jin X. Curcumol inhibits the expression of programmed cell death-ligand 1 through crosstalk between hypoxia-inducible factor-1α and STAT3 (T705) signaling pathways in hepatic cancer. Journal of Ethnopharmacology 2020;257:112835. [DOI: 10.1016/j.jep.2020.112835] [Cited by in Crossref: 15] [Cited by in F6Publishing: 28] [Article Influence: 7.5] [Reference Citation Analysis]
25 Kuriyama K, Higuchi T, Yokobori T, Saito H, Yoshida T, Hara K, Suzuki S, Sakai M, Sohda M, Higuchi T, Tsushima Y, Asao T, Kaira K, Kuwano H, Shirabe K, Saeki H. Uptake of positron emission tomography tracers reflects the tumor immune status in esophageal squamous cell carcinoma. Cancer Sci 2020;111:1969-78. [PMID: 32302443 DOI: 10.1111/cas.14421] [Cited by in Crossref: 3] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
26 Chen RQ, Xu XH, Liu F, Li CY, Li YJ, Li XR, Jiang GY, Hu F, Liu D, Pan F, Qiu XY, Chen XQ. The Binding of PD-L1 and Akt Facilitates Glioma Cell Invasion Upon Starvation via Akt/Autophagy/F-Actin Signaling. Front Oncol. 2019;9:1347. [PMID: 31850228 DOI: 10.3389/fonc.2019.01347] [Cited by in Crossref: 9] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
27 Hu M, Zhu Y, Mu D, Fan B, Zhao S, Yang G, Ma L, Zheng J, Yu J. Correlation of hypoxia as measured by fluorine-18 fluoroerythronitroimidazole (18F-FETNIM) PET/CT and overall survival in glioma patients. Eur J Nucl Med Mol Imaging 2020;47:1427-34. [PMID: 31776634 DOI: 10.1007/s00259-019-04621-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
28 London NR Jr, Rooper LM, Bishop JA, Xu H, Bernhardt LJ, Ishii M, Hann CL, Taube JM, Izumchenko E, Gaykalova DA, Gallia GL. Expression of Programmed Cell Death Ligand 1 and Associated Lymphocyte Infiltration in Olfactory Neuroblastoma. World Neurosurg 2020;135:e187-93. [PMID: 31785431 DOI: 10.1016/j.wneu.2019.11.112] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
29 Tamura R, Tanaka T, Akasaki Y, Murayama Y, Yoshida K, Sasaki H. The role of vascular endothelial growth factor in the hypoxic and immunosuppressive tumor microenvironment: perspectives for therapeutic implications. Med Oncol 2019;37:2. [PMID: 31713115 DOI: 10.1007/s12032-019-1329-2] [Cited by in Crossref: 54] [Cited by in F6Publishing: 79] [Article Influence: 18.0] [Reference Citation Analysis]
30 Litak J, Mazurek M, Grochowski C, Kamieniak P, Roliński J. PD-L1/PD-1 Axis in Glioblastoma Multiforme. Int J Mol Sci 2019;20:E5347. [PMID: 31661771 DOI: 10.3390/ijms20215347] [Cited by in Crossref: 37] [Cited by in F6Publishing: 57] [Article Influence: 12.3] [Reference Citation Analysis]
31 Jiang Y, Lin J, Zhang J, Lu S, Wang C, Tong Y. Expression of co-inhibitory molecules B7-H4 and B7-H1 in Epstein-Barr virus positive diffuse large B-cell lymphoma and their roles in tumor invasion. Pathol Res Pract 2019;215:152684. [PMID: 31679792 DOI: 10.1016/j.prp.2019.152684] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
32 Romano S, Tufano M, D'Arrigo P, Vigorito V, Russo S, Romano MF. Cell stemness, epithelial-to-mesenchymal transition, and immunoevasion: Intertwined aspects in cancer metastasis. Semin Cancer Biol 2020;60:181-90. [PMID: 31422157 DOI: 10.1016/j.semcancer.2019.08.015] [Cited by in Crossref: 6] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
33 Wang J, Leavenworth JW, Hjelmeland AB, Smith R, Patel N, Borg B, Si Y, King PH. Deletion of the RNA regulator HuR in tumor-associated microglia and macrophages stimulates anti-tumor immunity and attenuates glioma growth. Glia 2019;67:2424-39. [PMID: 31400163 DOI: 10.1002/glia.23696] [Cited by in Crossref: 11] [Cited by in F6Publishing: 17] [Article Influence: 3.7] [Reference Citation Analysis]
34 Mikkelsen K, Prakash MD, Kuol N, Nurgali K, Stojanovska L, Apostolopoulos V. Anti-Tumor Effects of Vitamin B2, B6 and B9 in Promonocytic Lymphoma Cells. Int J Mol Sci 2019;20:E3763. [PMID: 31374832 DOI: 10.3390/ijms20153763] [Cited by in Crossref: 9] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
35 Morimoto Y, Tamura R, Ohara K, Kosugi K, Oishi Y, Kuranari Y, Yoshida K, Toda M. Prognostic significance of VEGF receptors expression on the tumor cells in skull base chordoma. J Neurooncol 2019;144:65-77. [PMID: 31240525 DOI: 10.1007/s11060-019-03221-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
36 Sato M, Tamura R, Tamura H, Mase T, Kosugi K, Morimoto Y, Yoshida K, Toda M. Analysis of Tumor Angiogenesis and Immune Microenvironment in Non-Functional Pituitary Endocrine Tumors. J Clin Med 2019;8:E695. [PMID: 31100921 DOI: 10.3390/jcm8050695] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 7.0] [Reference Citation Analysis]
37 Takashima Y, Kawaguchi A, Hayano A, Yamanaka R. CD276 and the gene signature composed of GATA3 and LGALS3 enable prognosis prediction of glioblastoma multiforme. PLoS One 2019;14:e0216825. [PMID: 31075138 DOI: 10.1371/journal.pone.0216825] [Cited by in Crossref: 8] [Cited by in F6Publishing: 12] [Article Influence: 2.7] [Reference Citation Analysis]
38 Koh YW, Lee SJ, Han JH, Haam S, Jung J, Lee HW. PD-L1 protein expression in non-small-cell lung cancer and its relationship with the hypoxia-related signaling pathways: A study based on immunohistochemistry and RNA sequencing data. Lung Cancer 2019;129:41-7. [PMID: 30797490 DOI: 10.1016/j.lungcan.2019.01.004] [Cited by in Crossref: 12] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
39 Schulz D, Stancev I, Sorrentino A, Menevse AN, Beckhove P, Brockhoff G, Hautmann MG, Reichert TE, Bauer RJ, Ettl T. Increased PD-L1 expression in radioresistant HNSCC cell lines after irradiation affects cell proliferation due to inactivation of GSK-3beta. Oncotarget 2019;10:573-83. [PMID: 30728908 DOI: 10.18632/oncotarget.26542] [Cited by in Crossref: 9] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
40 Chen RQ, Liu F, Qiu XY, Chen XQ. The Prognostic and Therapeutic Value of PD-L1 in Glioma. Front Pharmacol 2018;9:1503. [PMID: 30687086 DOI: 10.3389/fphar.2018.01503] [Cited by in Crossref: 34] [Cited by in F6Publishing: 53] [Article Influence: 11.3] [Reference Citation Analysis]
41 Tamura R, Tanaka T, Ohara K, Miyake K, Morimoto Y, Yamamoto Y, Kanai R, Akasaki Y, Murayama Y, Tamiya T, Yoshida K, Sasaki H. Persistent restoration to the immunosupportive tumor microenvironment in glioblastoma by bevacizumab. Cancer Sci 2019;110:499-508. [PMID: 30467920 DOI: 10.1111/cas.13889] [Cited by in Crossref: 26] [Cited by in F6Publishing: 36] [Article Influence: 6.5] [Reference Citation Analysis]
42 Liu B, He X, Zhuo R, Cheng S. Tumor targeted genome editing mediated by a multi-functional gene vector for regulating cell behaviors. Journal of Controlled Release 2018;291:90-8. [DOI: 10.1016/j.jconrel.2018.10.018] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 3.5] [Reference Citation Analysis]
43 Lai YS, Wahyuningtyas R, Aui SP, Chang KT. Autocrine VEGF signalling on M2 macrophages regulates PD-L1 expression for immunomodulation of T cells. J Cell Mol Med 2019;23:1257-67. [PMID: 30456891 DOI: 10.1111/jcmm.14027] [Cited by in Crossref: 11] [Cited by in F6Publishing: 25] [Article Influence: 2.8] [Reference Citation Analysis]
44 Jiapaer S, Furuta T, Tanaka S, Kitabayashi T, Nakada M. Potential Strategies Overcoming the Temozolomide Resistance for Glioblastoma. Neurol Med Chir (Tokyo) 2018;58:405-21. [PMID: 30249919 DOI: 10.2176/nmc.ra.2018-0141] [Cited by in Crossref: 88] [Cited by in F6Publishing: 114] [Article Influence: 22.0] [Reference Citation Analysis]
45 Xing Y, Mi C, Wang Z, Zhang ZH, Li MY, Zuo HX, Wang JY, Jin X, Ma J. Fraxinellone has anticancer activity in vivo by inhibiting programmed cell death-ligand 1 expression by reducing hypoxia-inducible factor-1α and STAT3. Pharmacol Res 2018;135:166-80. [PMID: 30103001 DOI: 10.1016/j.phrs.2018.08.004] [Cited by in Crossref: 27] [Cited by in F6Publishing: 37] [Article Influence: 6.8] [Reference Citation Analysis]
46 Usman HA, Hernowo BS, Tobing MDL, Hindritiani R. The Major Role of NF-κB in the Depth of Invasion on Acral Melanoma by Decreasing CD8+ T Cells. J Pathol Transl Med 2018;52:164-70. [PMID: 29673240 DOI: 10.4132/jptm.2018.04.04] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
47 Takashima Y, Kawaguchi A, Kanayama T, Hayano A, Yamanaka R. Correlation between lower balance of Th2 helper T-cells and expression of PD-L1/PD-1 axis genes enables prognostic prediction in patients with glioblastoma. Oncotarget 2018;9:19065-78. [PMID: 29721184 DOI: 10.18632/oncotarget.24897] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 5.3] [Reference Citation Analysis]
48 Qiu XY, Hu DX, Chen WQ, Chen RQ, Qian SR, Li CY, Li YJ, Xiong XX, Liu D, Pan F, Yu SB, Chen XQ. PD-L1 confers glioblastoma multiforme malignancy via Ras binding and Ras/Erk/EMT activation. Biochim Biophys Acta Mol Basis Dis. 2018;1864:1754-1769. [PMID: 29510196 DOI: 10.1016/j.bbadis.2018.03.002] [Cited by in Crossref: 57] [Cited by in F6Publishing: 77] [Article Influence: 14.3] [Reference Citation Analysis]
49 Rom-Jurek EM, Kirchhammer N, Ugocsai P, Ortmann O, Wege AK, Brockhoff G. Regulation of Programmed Death Ligand 1 (PD-L1) Expression in Breast Cancer Cell Lines In Vitro and in Immunodeficient and Humanized Tumor Mice. Int J Mol Sci 2018;19:E563. [PMID: 29438316 DOI: 10.3390/ijms19020563] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 6.5] [Reference Citation Analysis]
50 Paolillo M, Boselli C, Schinelli S. Glioblastoma under Siege: An Overview of Current Therapeutic Strategies. Brain Sci 2018;8:E15. [PMID: 29337870 DOI: 10.3390/brainsci8010015] [Cited by in Crossref: 57] [Cited by in F6Publishing: 72] [Article Influence: 14.3] [Reference Citation Analysis]